Multicenter, Phase I/II Study to Evaluate the Safety, Tolerability, PK and Efficacy of SCT520FF in Patients With nAMD

计划入组 82 人 · 首次发布于 2024 年 11 月 4 日

Intravitreal Aflibercept for Macular Edema Due to Central Retinal Vein Occlusion

计划入组 51 人 · 首次发布于 2024 年 5 月 16 日

Safety, Tolerability, and Efficacy Study of UBX1325 in Patients With Neovascular Age-Related Macular Degeneration (ENVISION)

计划入组 51 人 · 首次发布于 2022 年 3 月 11 日

Aflibercept(Eylea, Zaltrap, Yesafili, Eydenzelt, Ahzantive, Afqlir, Baiama, Opuviz, Pavblu, Mynzepli, Vgenfli, Eiyzey)

Rx

Aflibercept/Nesvacumab

Eylea Biosimilar(Alteogen, Inc.)

DAS-MG, Inc

MEREO BIOPHARMA 2 LIMITED

United Kingdom

UpJohn US 2 LLC

United States

EMA Approves Pre-filled Syringe for Eylea 8 mg, Enhancing AMD and DME Treatment

EYLEA HD Shows Sustained Vision Gains in DME Patients Over Three Years

Samchundang Pharm Reaches Global Settlement in Eylea Biosimilar Patent Dispute, Clearing Path for SCD411 Commercialization